APP下载

Peficitinib治疗类风湿关节炎疗效和安全性的系统评价

2020-04-20刘鑫徐昌静钟小燕赵丹洁余彬黄毅岚

中国药房 2020年7期
关键词:类风湿关节炎Meta分析

刘鑫 徐昌静 钟小燕 赵丹洁 余彬 黄毅岚

摘 要 目的:系統评价JAK抑制剂Peficitinib治疗类风湿关节炎(RA)的疗效和安全性,以为临床治疗RA提供循证参考。方法:计算机检索PubMed、Embase、The Cochrane Library、中国期刊全文数据库、维普网和万方数据库,检索时限均为建库起至2019年9月,收集Peficitinib(试验组)对比安慰剂 (对照组)治疗RA的疗效和安全性的随机对照试验(RCT),对符合纳入标准的临床研究进行资料提取后,采用Cochrane系统评价员手册5.1.0提供的偏倚风险评估工具进行质量评价,采用Stata 16统计软件对疗效[达到美国风湿病学会20%缓解标准的患者比例(ACR20)、ACR50和ACR70,以红细胞沉降率计算的28个关节疾病活动指数<2.6的患者比例(DAS28-ESR<2.6),以C反应蛋白计算的28个关节疾病活动指数<2.6的患者比例(DAS28-CRP<2.6)等]和安全性(总不良反应发生率)进行Meta分析。结果:共纳入5项RCT,合计1 773例患者。Meta分析结果显示,试验组患者ACR20{总体[RR=1.85,95%CI(1.45,2.36),P<0.001]、50 mg[RR=1.51,95%CI(1.04,2.20),P=0.030]、100 mg[RR=2.01,95%CI(1.29,3.13),P=0.002]、150 mg[RR=2.39,95%CI(1.58,3.61),P<0.001]}、ACR50{总体[RR=2.38,95%CI(1.65,3.42),P<0.001]、100 mg[RR=2.87,95%CI(1.61,5.11),P<0.001]、150 mg[RR=3.52,95%CI(1.78,6.96),P<0.001]}、ACR70{总体[RR=2.51,95%CI(1.52,4.14),P<0.001]、100 mg[RR=3.50,95%CI(1.62,7.58),P=0.001]、150 mg[RR=4.59,95%CI(1.47,14.30),P=0.009]}、DAS28-ESR<2.6{总体[RR=4.83,95%CI(3.20,7.28),P<0.001]、100 mg[RR=5.37,95%CI(2.68,10.77),P<0.001]、150 mg[RR=7.44,95%CI(3.78,14.65),P<0.001]}、DAS28-CRP<2.6{总体[RR=3.41,95%CI(2.65,4.39),P<0.001]、100 mg[RR=4.00,95%CI(2.67,5.99),P<0.001]、150 mg[RR=4.45,95%CI(2.99,6.63),P<0.001]}均显著高于对照组,差异均有统计学意义。安全性方面,两组患者总不良反应发生率比较,差异均无统计学意义[RR=1.05,95%CI(0.94,1.16),P=0.395]。结论:Peficitinib 100 mg或150 mg,每日1次用于治疗RA,在改善ACR20、ACR50和ACR70、DAS28-ESR<2.6、DAS28-CRP<2.6方面优于安慰剂,不良反应轻微可耐受,可能会成为治疗RA的新选择。

关键词 Peficitinib;类风湿关节炎;JAK抑制剂;Meta分析

ABSTRACT   OBJECTIVE: To systematically evaluate the efficacy and safety of peficitinib for treating rheumatoid arthritis (RA), and to provide evidence-based reference for the clinical treatment of RA. METHODS: Retrieved from PubMed, Embase, The Cochrane Library, CJFD, VIP and Wanfang database during from their establishment to September 2019, randomized controlled trials (RCTs) about the efficacy and safety of Peficitinib (trial group) versus placebo (control group) in the treatment of RA were collected. The risk of bias assessment tool provided in Cochrane System Evaluator Manual 5.1.0 was used to evaluate the quality after data extracted from clinical studies which met the inclusion criteria. Meta-analysis of the efficacy [the proportion of patients who met the American College of Rheumatology 20% improvement criteria (ACR20), ACR50, ACR70, the proportion of the patients with 28 joint disease activity index<2.6 calculated by erythrocyte sedimentation rate (DAS28-ESR<2.6), the proportion of patients with 28 joint disease activity index<2.6 calculated by C-reactive protein (DAS28-CRP<2.6), etc.] and safety (incidence of total ADR) was performed by using Stata 16 statistical software. RESULTS: Totally 5 RCTs were included, involving 1 773 patients. Meta-analysis results showed that ACR20 {total [RR=1.85,95%CI(1.45,2.36),P<0.001], 50 mg[RR=1.51,95%CI(1.04,2.20),P=0.030], 100 mg[RR=2.01,95%CI(1.29,3.13),P=0.002], 150 mg[RR=2.39,95%CI(1.58,3.61),P<0.001]}, ACR50{total [RR=2.38,95%CI(1.65,3.42),P<0.001], 100 mg[RR=2.87,95%CI(1.61,5.11),P<0.001],150 mg[RR=3.52,95%CI(1.78,6.96),P<0.001]}, ACR70{total [RR=2.51,95%CI(1.52,4.14),P<0.001], 100 mg[RR=3.50,95%CI(1.62,7.58),P=0.001], 150 mg[RR=4.59,95%CI(1.47,14.30),P=0.009]}, DAS28-ESR<2.6{total [RR=4.83,95%CI(3.20,7.28),P<0.001],100 mg[RR=5.37,95%CI(2.68,10.77),P<0.001], 150 mg[RR=7.44,95%CI(3.78,14.65),P<0.001]} and DAS28-CRP<2.6{total [RR=3.41,95%CI(2.65,4.39),P<0.001], 100 mg[RR=4.00,95%CI(2.67,5.99),P<0.001], 150 mg[RR=4.45,95%CI(2.99,6.63),P<0.001]} in trial group were significantly higher than control group, with statistical significance. In term of safety, there was no statistical significance in the incidence of total ADR [RR=1.05,95%CI(0.94,1.16),P=0.395] between 2 groups. CONCLUSIONS: For the treatment of RA, 100 mg or 150 mg peficitinib once per day is superior to placebo in terms of ACR20, ACR50 and ACR70, DAS28-ESR<2.6, DAS28-CRP<2.6;  the adverse events are mild and tolerable and it may be a new treatment option for RA.

KEYWORDS   Peficitinib; Rheumatoid arthritis; JAK inhibitor; Meta-analysis

类风湿关节炎(Rheumatoid arthritis,RA)是一种以持续性滑膜炎、进行性关节损伤、畸形甚至残疾为主要临床表现的慢性自身免疫性疾病,可发生于任何年龄阶段,影响着全世界大约1%的人口,在我国的发病率为0.42%,且女性发病率显著高于男性[1-3]。临床上对于RA的治疗,均明确推荐首选传统类改善病情抗风湿药物(DMARDs)甲氨蝶呤;对于单药治疗后仍然是中/高疾病活动度的患者,推荐给予DMARDs或生物类DMARDs联合使用[4-5]。但由于甲氨蝶呤、生物制剂等不能对所有患者产生广泛且持久的疗效,因此临床上迫切需要寻找新的RA治疗方案。近年来,JAK家族的非受体蛋白酪氨酸激酶被认为是RA治疗的新靶点,JAK抑制剂口服小分子靶向药物成为了治疗RA的新选择,截至2019年8月,Tofacitinib、Baricitinib和Upadacitinib被美国食品药品监督管理局(FDA)批准用于RA的治疗,Peficitinib(研究代码:ASP015K、JNJ-54781532)被日本医药品医疗器械综合机构(PMDA)批准在日本上市[6]。……

登录APP查看全文

猜你喜欢

类风湿关节炎Meta分析
藏药内服外浴配合甲氨蝶呤治疗类风湿关节炎80例临床观察
藏药五味甘露汤联合小叶毛球莸药浴治疗类风湿关节炎疗效观察
类风湿关节炎蒙医药治疗现状与展望
类风湿关节炎的诊断及其药物治疗研究进展
结直肠进展腺瘤发生率的Meta分析
中西医结合治疗类风湿关节炎的临床疗效观察
血小板与冷沉淀联合输注在大出血临床治疗中应用的Meta分析
细辛脑注射液治疗慢性阻塞性肺疾病急性加重期疗效的Meta分析
中药熏洗治疗类风湿关节炎疗效的Meta分析
丹红注射液治疗特发性肺纤维化临床疗效及安全性的Meta分析